Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring
IRVINE, Calif. and DUBAI, United Arab Emirates, Feb. 10, 2011 /PRNewswire/ -- Mafraq Hospital and Masimo (Nasdaq: MASI) jointly announced the hospital-wide conversion of Mafraq Hospital to Masimo rainbow® SET Pulse CO-Oximetry™ technology for advanced noninvasive patient monitoring capabilities. The conversion makes Mafraq Hospital the first hospital in the UAE to feature Masimo's technologically and clinically-advanced oximetry and noninvasive patient monitoring solutions.
The Masimo rainbow SET Pulse CO-Oximetry technology platform allows hospitals to noninvasively measure and continuously monitor multiple blood constituents and physiological parameters that previously required invasive procedures—including: total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and acoustic respiration rate (RRa™), in addition to the 'gold-standard' Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR). The oximetry standard-of-care at leading hospitals worldwide, Masimo rainbow SET provides immediate real-time results that enable clinicians to more rapidly assess patients and detect and treat adverse, potentially life-threatening conditions earlier.
"Mafraq Hospital takes great pride in the skills and experience of its physicians and the fact that we have some of the wor